Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 1/20 | 0.71 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.71 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.43 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5534 | 0.83 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CKMT2APOLB | |
| SCHEMBL5784 | 0.81 | ADRA2A (0.71) | ADRA2AADRA2BADRA2CKMT2APOLB | |
| SCHEMBL5586 | 0.78 | ADRA2A (0.67) | ADRA2AADRA2BADRA2CKMT2APOLB | |
| SCHEMBL6526 | 0.78 | ADRA2A (0.66) | ADRA2AADRA2BADRA2CKMT2APOLB | |
| SCHEMBL5896 | 0.75 | ADRA2A (0.54) | ADRA2AADRA2BADRA2CKMT2APOLB | |
| SCHEMBL6475 | 0.75 | ADRA2A (0.62) | ADRA2AADRA2BADRA2CKMT2APOLB | |
| SCHEMBL20246768 | 0.75 | KMT2A (0.47) | ADRA2AADRA2BADRA2CKMT2AALOX15 | |
| Hydrochloric Acid SCHEMBL10369396 | 0.74 | ADRA2A (0.60) | ADRA2AADRA2BADRA2CKMT2APOLB | |
| SCHEMBL10817884 | 0.73 | ADRA2A (0.59) | ADRA2AADRA2BADRA2CKMT2APOLB | |
| SCHEMBL1669804 | 0.72 | ADRA2A (0.67) | ADRA2AADRA2BADRA2CKMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2491017-B1 | ALPHA ADRENERGIC RECEPTOR MODULATORS | ALLERGAN INC (US) | 2014-08-27 | — | — | EP | claimed |
| US-20120238615-A1 | Alpha adrenergic receptor modulators | ALLERGAN, INC. (US) | 2012-09-20 | — | — | US | claimed |
| CN-102666484-A | Adrenergic receptor modulators | ALLERGAN INC | 2012-09-12 | — | — | CN | claimed |
| EP-2491017-A1 | ALPHA ADRENERGIC RECEPTOR MODULATORS | Allergan, Inc. (US) | 2012-08-29 | — | — | EP | claimed |
| WO-2011050030-A1 | ALPHA ADRENERGIC RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2011-04-28 | — | — | WO | claimed |
| EP-2491017-B1 | ALPHA ADRENERGIC RECEPTOR MODULATORS | ALLERGAN INC (US) | 2014-08-27 | — | — | EP | disclosed |
| US-20120238615-A1 | Alpha adrenergic receptor modulators | ALLERGAN, INC. (US) | 2012-09-20 | — | — | US | disclosed |
| CN-102666484-A | Adrenergic receptor modulators | ALLERGAN INC | 2012-09-12 | — | — | CN | disclosed |
| EP-2491017-A1 | ALPHA ADRENERGIC RECEPTOR MODULATORS | Allergan, Inc. (US) | 2012-08-29 | — | — | EP | disclosed |
| WO-2011050030-A1 | ALPHA ADRENERGIC RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2011-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238615-A1 | Alpha adrenergic receptor modulators | ADRA2C, ADRB2, ADRB1 | ADRA2A 4/4885ADRA2B 6/4885ADRA2C 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.